GeneCraft
GeneCraft is a pre-clinical-stage biotech company dedicated to improving treatment and clinical outcomes for patients through gene therapy that harnesses the innate oncogene defense system. The company focuses on developing transformational gene therapies for cancer patients with K-RAS mutations, aiming to overcome the unconquered Pan K-RAS cancer and improve lives beyond today's standard of care.
Industries
Nr. of Employees
small (1-50)
GeneCraft
1, Chungdae-ro, Seowon-gum Cheongju-si, Chungcheongbuk-do, Republic of Korea, E-9/480 (Chungbuk National University)
Patents
Nucleic acid molecule comprising asymmetrically modified ITR for improving expression rate of inserted gene, and use thereof
US-11993783-B1
View DetailsModified complex platform of adeno-associated virus with improved rate of expression of loaded genes and reduced genotoxicity
US-11891617-B1
View DetailsAdeno-associated virus complex with improved expression of RUNX3 gene and uses for preventing or treating KRAS mutated lung cancer
US-11767541-B1
View Details
Nucleic acid molecule comprising asymmetrically modified ITR for improving expression rate of inserted gene, and use thereof
US-11993783-B1
View DetailsModified complex platform of adeno-associated virus with improved rate of expression of loaded genes and reduced genotoxicity
US-11891617-B1
View DetailsAdeno-associated virus complex with improved expression of RUNX3 gene and uses for preventing or treating KRAS mutated lung cancer
US-11767541-B1
View DetailsProducts
Gene therapy candidate for pan K-RAS mutated lung cancer
A preclinical-stage gene therapy program designed to target pan K-RAS mutations in lung cancer by selectively inducing death of mutant cancer cells.
AAV-based gene delivery platform
An AAV-centered platform for designing and packaging gene constructs into therapeutics intended for oncology applications.
Gene therapy candidate for pan K-RAS mutated lung cancer
A preclinical-stage gene therapy program designed to target pan K-RAS mutations in lung cancer by selectively inducing death of mutant cancer cells.
AAV-based gene delivery platform
An AAV-centered platform for designing and packaging gene constructs into therapeutics intended for oncology applications.
Services
Collaborative research partnerships to identify and advance novel gene therapy approaches for oncology, including preclinical program support and translational planning.
Support for forming strategic alliances, memoranda of understanding, and financing arrangements to advance development and production of gene therapy candidates.
Collaborative research partnerships to identify and advance novel gene therapy approaches for oncology, including preclinical program support and translational planning.
Support for forming strategic alliances, memoranda of understanding, and financing arrangements to advance development and production of gene therapy candidates.
Expertise Areas
- Gene therapy development
- Oncology targeting K-RAS mutations
- AAV vector platform development
- Preclinical translational research
Key Technologies
- Gene therapy
- AAV vector engineering
- Transcription factor (RUNX3) mechanistic research
- Selective oncogene-targeted therapeutics